NCT06614205

Brief Summary

The hypothesis for this study is that there is a dose-response relationship in patients treated with 177Lu-DOTATATE for meningiomas.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 2024

Shorter than P25 for all trials

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 6, 2024

Completed
4 months until next milestone

First Posted

Study publicly available on registry

September 26, 2024

Completed
1 month until next milestone

Study Start

First participant enrolled

November 1, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2025

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 25, 2025

Completed
Last Updated

March 4, 2025

Status Verified

February 1, 2025

Enrollment Period

2 months

First QC Date

June 6, 2024

Last Update Submit

February 28, 2025

Conditions

Meningioma of Brain

Keywords

meningiomatheragnosticdosimetry

Outcome Measures

Primary Outcomes (1)

  • Diagnostic accuracy for progression free survival

    Accuracy of tumor dosimetry to predict 6-month progression-free survival.

    Day 1

Secondary Outcomes (1)

  • Diagnostic accuracy for overal survival

    Day 1

Study Arms (1)

Patients treated with 177Lu-DOTATATE for meningioma

Patients treated with 177Lu-DOTATATE for meningioma at the Nancy's hospital who met the treatment criteria of the Compassionate Prescribing Framework and received a scintigraphy at D1, D4 and D7 (± 1 day)

Diagnostic Test: tumoral dosimetry by scintigraphy

Interventions

tumoral dosimetry by scintigraphyDIAGNOSTIC_TEST

The tumoral dosimetry has been done on patient after treatment by 177Lu-DOTATATE Theses patients performed a scintigraphy exam at D1, D4 and D7 after the treatment

Patients treated with 177Lu-DOTATATE for meningioma

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

patients treated with 177Lu-DOTATATE for meningioma at Nancy University Hospital

You may qualify if:

  • patients treated for menigioma at nancy hospital
  • patients who performed 3 scintigraphics exams during there treatment

You may not qualify if:

  • patients deprived of liberty
  • patient who refused to collect data retrospectively

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

CHRU de NANCY

Vandœuvre-lès-Nancy, 54511, France

Location

Nuclear medicine Department CHRU de NANCY

Vandœuvre-lès-Nancy, 54511, France

Location

MeSH Terms

Conditions

Meningioma

Condition Hierarchy (Ancestors)

Neoplasms, Nerve TissueNeoplasms by Histologic TypeNeoplasmsNeoplasms, Vascular TissueMeningeal NeoplasmsCentral Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNervous System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

June 6, 2024

First Posted

September 26, 2024

Study Start

November 1, 2024

Primary Completion

January 1, 2025

Study Completion

February 25, 2025

Last Updated

March 4, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

Locations

FR(2)